Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)
NCT03520751Phase 2Withdrawn
- Sponsor
- Nationwide Children's Hospital
- Start
- Apr 2027
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of scAAV1.tMCK.NTF3 in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Nationwide Children's Hospital. Planned start Apr 2027; status: withdrawn.
02
Drugs
scAAV1.tMCK.NTF3
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT03520751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520751.